Bemnifosbuvir/Ruzasvir

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameBemnifosbuvir/Ruzasvir
Drug Alias NameBEM/RZR
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsRNA-directed RNA polymerase inhibitorsNonstructural protein 5A inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseRNA-directed RNA polymeraseNonstructural protein 5A
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[16] 
CombinationsYes BemnifosbuvirRuzasvir
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAtea Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAtea Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A